Previous 10 | Next 10 |
2023-05-09 12:21:06 ET ADC Therapeutics SA (ADCT) Q1 2023 Earnings Conference Call May 9, 2023 08:30 AM ET Company Participants Amanda Loshbaugh - Investor Relations Manager Ameet Mallik - Chief Executive Officer Kristen Harrington-Smith - Chief Commercial Office...
2023-05-09 07:10:32 ET ADC Therapeutics press release ( NYSE: ADCT ): Q1 Non-GAAP EPS of -$0.53. Revenue of $18.99M (-59.2% Y/Y) misses by $1.1M . The Company reaffirms the following guidance based on its current business plan: ZYNLONTA FY 2023 net product ...
1Q 2023 ZYNLONTA ®1 net sales increased 15% and operating expenses decreased 19% year-over-year 2 ; FY 2023 guidance reaffirmed for ZYNLONTA double-digit net sales growth and reduction in operating expenses as compared to FY 2022 Implementing new go-to-market model to help dr...
ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023 at 8:30 a.m. EDT to report financial results for the first quarter 2023 and provide business updates. To access the conference call, please register here . Registr...
2023-03-23 05:53:31 ET The following slide deck was published by ADC Therapeutics SA in conjunction with this event. For further details see: ADC Therapeutics (ADCT) Presents At 44th Annual Institutional Investors Conference - Slideshow
ADC Therapeutics SA (NYSE: ADCT) today announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, has been filed with the U.S. Securities and Exchange Commission (the “SEC”). ADC Therapeutics’ Annual Report on Form 20-F can be accessed by visiti...
ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the Cowen 43 rd Annual Health Care Conference in Boston, MA, on Tuesday, March 7th at 2:50 p.m. ET. A live webcast of the presentation will be available via the ...
ADC Therapeutics SA (ADCT) Q4 2022 Results Conference Call February 28, 2023 08:30 AM ET Company Participants Amanda Hamilton - IR Manager Ameet Mallik - CEO Kristen Harrington-Smith - Chief Commercial Officer Mohamed Zaki - Chief Medical Officer Pepe Carmona -...
ADC Therapeutics press release ( NYSE: ADCT ): Q4 Non-GAAP EPS of -$0.10 misses by $0.05 . Revenue of $19.8M (+16.4% Y/Y) misses by $45.69M . The company expected to grow ZYNLONTA FY 2023 net product sales by a double-digit percentage year-over-year. For further ...
ZYNLONTA ® (loncastuximab tesirine-lpyl) net sales of $19.8 million in Q4 2022, +16.5% year-over-year, and $74.9 million for the full year (FY) 2022 FY 2023 ZYNLONTA net sales expected to grow by a double-digit percentage year-over-year Multiple data catalysts expecte...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...